| Ticker: ILABY | Viale Monza 338 | |
| Exchange: NASDAQ-National Market | Milano, Foreign 20128 | |
| Industry: Manufacturing |
| Type of Shares: | American Depositary Receipts | Filing Date: | 9/30/96 | |
| U.S. Shares: | 3,218,933 | Offer Date: | 10/28/96 | |
| Non-U.S. Shares: | 2,145,956 | Filing Range: | $15.00 - $17.00 | |
| Primary Shares: | 3,125,000 | Offer Price: | $12.00 | |
| Secondary Shares: | 2,239,889 | Gross Spread: | $0.78 | |
| Offering Amount: | $85,838,224 | Selling: | $0.48 | |
| Expenses: | $2,250,000 | Reallowance: | $0.10 | |
| Shares Out After: | 16,609,500 |
| Manager | Tier | Phone |
| Salomon Brothers Inc. | Lead Manager | (212) 783-2947 |
| Dillon, Read & Co. Inc. | Co-manager | (212) 906-7000 |
| UBS Securities Inc. | Co-manager | (212) 230-4000 |
| Auditor: Arthur Andersen | |||||
| Audited Income | Latest Unaudited Income | Prior Unaudited Income | Balance Sheet | ||
| 11/30/95 | 5/31/96 | 5/31/96 | |||
| Revenue: | $265.66 | $129.40 | Assets: | $375.93 | |
| Net Income: | $2.28 | $0.71 | Liabilities: | $313.37 | |
| EPS: | $0.20 | $0.06 | Equity: | $62.56 | |
Note: Dollar amounts are in U.S. millions; Audited figures expressed as full year, unaudited figures are partial year | |||||
| Business Description |
| The company is a worldwide developer, manufacturer and distributor of in vitro diagnostics instruments and related reagents, controls, other consumables and services for use primarily in hospitals and independent clinical laboratories. IVD tests are used to identify and measure substances in a patient's tissue, blood or urine sample and are an integral part of the cost-effective delivery of a patient's care. The information generated from these tests is essential to the most basic diagnostic needs, such as cholesterol levels, and the management of acutely ill patients where time-sensitive information is critical. The company has three major IVD product lines which are distributed around the world: critical care, hemostasis and clinical chemistry, which represented 32%, 30% and 18%, respectively, of fiscal 1995 net revenues. In both the critical care and hemostasis markets, the company believes that it is the second largest worldwide supplier after giving effect to the acquisition of MSS and Chromogenix. In each of its three major product lines, the company utilizes a systems approach by providing its customers with instruments, reagents, controls, other consumables and services in a single system. The company has both global manufacturing capability and an extensive sales and distribution network which enables it to distribute its products in over 90 countries. The company's revenue is generated from a diverse global customer base, with fiscal 1995 net revenues derived 62% from Europe, 31% from the United States and 7% from the rest of the world. |
| Use of Proceeds |
| The proceeds from the proposed offering will be used to repay subordinated loans issued by the company in connection with financing the acquisition of Chromogenix and borrowings under short-term credit lines. |
©1996 IPO Data Systems, Inc. - All rights reserved.